Novartis offers $38.5 billion for rest of Alcon
This article was originally published in Scrip
Executive Summary
Novartis is to acquire Nestlé's remaining 52% share in Alcon for $28.1 billion as part of a move to acquire the whole of the speciality eye-care company.